<DOC>
	<DOCNO>NCT01967719</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetic ( PK ) profile ( rate amount nicotine absorb ) single use THS 2.2 Menthol ( mTHS 2.2 ) compare single use menthol conventional cigarette ( mCC ) nicotine nasal spray ( NNS ) .</brief_summary>
	<brief_title>Nicotine Pharmacokinetic Profile Safety Tobacco Heating System 2.2 Menthol ( THS 2.2 Menthol )</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Subject age 22 65 year ( inclusive ) . Smoking , healthy subject judge Investigator . Subject smoke least 10 commercially available menthol CCs per day ( brand restriction ) last 4 week . Subject smoke least last 3 consecutive year . As per Investigator judgment , subject participate study reason ( e.g. , medical , psychiatric , and/or social reason ) . Subject received medication within 14 day within 5 halflives drug ( whichever longer ) impact CYP2A6 activity . Female subject pregnant breast feeding . Female subject agree use acceptable method effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Nicotine absorption</keyword>
	<keyword>Candidate modify risk tobacco product</keyword>
	<keyword>Conventional cigarette</keyword>
	<keyword>Nicotine replacement therapy : nasal spray</keyword>
</DOC>